MediBeacon Enters into $30 Million Investment and Exclusive Commercialization Partnership in Greater China with Huadong Medicine

MediBeacon and Huadong Medicine will collaboratively work to reach regulatory approval on MediBeacon's entire portfolio of assets inGreater China ST. LOUIS, July 31, 2019 /PRNewswire/ -- MediBeacon Inc., whose largest shareholder is Pansend Life Sciences, LLC, a subsidiary of HC2 Holdings, Inc. ...

2019-07-31 20:30 1926

FDA Grants Breakthrough Device Status for MediBeacon's Transdermal GFR Measurement System

MediBeacon's Breakthrough Device is Intended to Measure GFR in Patients with Impaired or Normal Kidney Function ST. LOUIS, Oct. 22, 2018 /PRNewswire/ -- MediBeacon Inc ., whose largest shareholder is Pansend Life Sciences of HC2 Holdings, Inc. (NYSE MKT: HCHC), announ...

2018-10-22 18:15 405